HC Wainwright Reaffirms “Neutral” Rating for Portage Biotech (NASDAQ:ALP)

Posted by on Aug 17th, 2026

Portage Biotech (NASDAQ:ALP – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $0.25 target price on the stock. HC Wainwright’s price objective points to a potential upside of 44.18% from the stock’s previous close.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Portage Biotech in a research report on Friday, July 24th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $0.25.

Read Our Latest Stock Report on ALP

Portage Biotech Stock Performance

Shares of NASDAQ ALP opened at $0.17 on Monday. Portage Biotech has a 12 month low of $0.15 and a 12 month high of $13.80. The company has a market cap of $4.07 million, a price-to-earnings ratio of -0.02 and a beta of 0.61. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $0.29 and a 200-day simple moving average of $0.35.

Portage Biotech (NASDAQ:ALP – Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The company reported $0.48 earnings per share for the quarter. The company had revenue of $0.05 million during the quarter.

Portage Biotech Company Profile

(Get Free Report)

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.

Read More

Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.